Lewy body pathology in Alzheimer's disease

Journal of Molecular Neuroscience

Volumn 17, Issue 2, 2001, Pages 225-232

  Kotzbauer, P T ^a   Trojanowski, J Q ^a   Lee, V M Y ^a  

^a NONE   (United States)

Author keywords

Alzheimer's disease; Amyloid plaques; A amyloid; Dementia with Lewy bodies; Familial Alzheimer' s Disease; Lewy bodies; Neurofibrillary tangles; Oxidative stress; Parkinson's disease; Tau protein; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRAIN STEM; DEMENTIA; ENTORHINAL CORTEX; HUMAN; LEWY BODY; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; HUMANS; LEWY BODIES; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; POINT MUTATION; SYNUCLEINS; TAU PROTEINS;

EID: 0035169488     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:17:2:225     Document Type: Article

References (80)

1. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
2. Pure autonomic failure in association with human alpha-synucleinopathy
3. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein
4. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
5. Neural expression profile of alpha-synuclein in developing human cortex
6. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores
7. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
8. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
9. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
10. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with A beta amyloid
11. Wildtype but not Parkinson's disease-related ala-53 → Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli
12. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
13. A Drosophila model of Parkinson's disease
14. Neuropathology of Parkinson's disease
15. The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings
16. Clinical-neuropathological correlations in Alzheimer's disease and related dementias
17. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
18. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
19. Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases
20. Lewy bodies of Parkinson's disease contain neurofilament antigens
21. Dementia with Lewy bodies
22. Clinical and neuropathological correlates of dementia with Lewy bodies
23. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry
24. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
25. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa
26. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
27. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to establish a registry for Alzheimer's disease, Part XIX
28. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development
29. Alpha-synuclein promotes mitochondrial deficit and oxidative stress
30. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease
31. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease
32. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
33. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: Comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type. Parkinson's diseas and non-demented elderly control patients
34. Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions
35. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease
36. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins
37. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
38. Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure
39. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein
40. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
41. Diffusible nonfibrillar ligands derived from A beta1-42 are potent central nervous system neurotoxins
42. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
43. The synuclein family
44. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult
45. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
46. The frequency of Lewy bodies in a consecutive autopsy series
47. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
48. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease
49. Predictors of progression in patients with AD and Lewy bodies
50. Ubiquitin carboxyl-terminal hydrolase (PGP9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases
51. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
52. 2+ homeostasis in Alzheimer's disease
53. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
54. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations
55. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
56. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation
57. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury
58. Alpha-synuclein shares physical and functional homology with 14-13-3 proteins
59. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity
60. Abnormalities of the electron transport chain in idiopathic Parkinson's disease
61. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
62. Mechanisms of MPTP toxicity
63. Inflammation and Alzheimer's disease pathogenesis
64. Induction of neuronal death by alpha-synuclein
65. Mitochondrial complex I deficiency in Parkinson's disease
66. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders
67. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases
68. Alzheimer's disease: Genes, proteins, and therapy
69. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies
70. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies
71. Alpha-synuclein in filamentous inclusions of lewy bodies from Parkinson's disease and dementia with lewy bodies
72. Alpha-synuclein in Lewy bodies
73. Origin and functional consequences of the complex I defect in Parkinson's disease
74. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein
75. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
76. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity
77. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies
78. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
79. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons
80. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells